



STUDI CLINICI SU COVID-19 CONCLUSI CON RISULTATI PUBBLICATI

ID	URL	TITOLO	RISULTATI
2020-000890-25	https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/	Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine	https://www.sciencedirect.com/science/article/pii/S0924857920300996
CHICTR2000029308	http://www.chictr.org.cn/showproj.aspx?proj=48684	A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true
CHICTR2000029559	http://www.chictr.org.cn/showproj.aspx?proj=48880	Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)	https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1.full.pdf
CHICTR2000029600	http://www.chictr.org.cn/showproj.aspx?proj=49042	Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)	https://reader.elsevier.com/reader/sd/pii/S2095809920300631?token=A28CA1B43E646EFBA54D61F15A05C13723D1BFA784EAC81E632C0FB769F1BD4BA964D4E304CB8D9EAA24DF528709668A
CHICTR2000030254	http://www.chictr.org.cn/showproj.aspx?proj=50137	the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study	https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1.full.pdf
NCT04252885	https://ClinicalTrials.gov/show/NCT04252885	The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI)	https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038984.full.pdf
NCT04261517	https://ClinicalTrials.gov/show/NCT04261517	Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19	http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03#1
NCT04275245	https://ClinicalTrials.gov/show/NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia	https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf
NCT04422561	https://clinicaltrials.gov/ct2/show/study/NCT04422561	Prophylactic Ivermectin in COVID-19 Contacts	https://clinicaltrials.gov/ct2/show/results/NCT04422561
NCT04475588	https://clinicaltrials.gov/ct2/show/study/NCT04475588	Efficacy and Safety of Itolizumab in COVID-19 Complications	https://clinicaltrials.gov/ct2/show/results/NCT04475588
NCT04523831	https://ClinicalTrials.gov/show/NCT04523831	Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection	https://clinicaltrials.gov/ct2/show/results/NCT04523831



NCT0449 1240	https://clinicaltrials.gov/show/NCT04491240	Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia. (COVID-19EXO)	https://clinicaltrials.gov/ct2/show/results/NCT04491240
NCT0439 0022	https://ClinicalTrials.gov/show/NCT04390022	Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission	https://clinicaltrials.gov/ct2/show/results/NCT04390022